Attento — advance in the treatment of arterial hypertension

Yu.M. Sirenko, O.L. Rekovets

Abstract


The article deals with the problem of treatment for arterial hypertension. A review of a number of researches aimed at studying the effectiveness of the combination of olmesartan and amlodipine in this pathology is presented.


Keywords


arterial hypertension; treatment; olmesartan; amlodipine; fixed combinations; overview

References


https: //www.ncbi.nlm.nih.gov/pubmed/?term = arterial + hypertension.

Falaschetti et al. // Lancet. 2014; 383: 1912-19.

Kornelia Kotsev et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 // European countries Journal of Preventive Cardiology. 2015. 1-13. doi: 10.1177/2047487315569401

Omid Fatemi et al. Improvement in All-Cause Morta­-

lity With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension // The Journal of Clinical Hypertension. 2016; Vol. 18, № 1.

Debie L. et al. // The Journal of Clinical Hypertension. 2015; Vol. 17, № 5.

Whelton P.K. et al. High Blood Pressure Clinical Practice Guideline. 2017. http: //hyper.ahajournals.org/lookup/suppl/doi: 10.1161/HYP.0000000000000065/-/DC1

Thomas J. Wang et al. Is a DASH of Salt All We Need? // J. Am. Coll. Cardiol. 2017; 70(23): 2849-2851.

Dusing R. Adverse events, compliance and changes in the­rapy // Curr. Hypertens Rep. 2001; 3: 488-492.

Ian H. de Boer еt al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association // Diabetes Care. 2017; 40: 1273-1284.

Fleg J.L., Evans G.W., Margolis K.L. et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance // Hypertension. 2016; 68: 888-895.

Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. 2008; 358: 1547-1559.

Di Stefano C. et al. Orthostatic hypotension in a cohort of hypertensive patients reffering to a hypertension clinic // Journal of Human Hypertension. 2015; 29: 599-603.

Hazel Mae A. Abraham et al. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases // Drug Saf. 2015 Jan; 38(1): 33-54.

Kiya Y. et al. Clinical and Pharmacotherapeutic Relevance of the Double Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan // Clin. Exp. Hypertens. 2010; 32(2): 129-136.

Jun Agata et al. Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme // Hypertension Research. 2006. doi: 10.1291/hypres.29.865

Furuhashi M. et al. Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker // Am. J. Hypertens. 2014 May 18.

Furuhashi M. et al. Possible increase in urinary angiotensin­converting enzyme 2 by olmesartan, an angiotensin II receptor blocker, in hypertensive patients // European Heart Journal. 2014; 35 (Abstract Supplement), 66.

Akira Sezai et al. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study) // Ann Thorac Cardiovasc Surg Advance Published Date: April 18, 2016, doi: 10.5761/atcs.oa.16-00054.

Fabia et al. // J. Hypertens. 2007; 25: 1327-36.

Durán A.M., Corcuera J.O. Antihypertensive Efficacy of Fimasartan and Additional Benefits in Patients with Renal Dysfunction // Ann. Clin. Exp. Hypertension. 2017; 5(1): 1046.

Bakris G.L. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure // J. Clin. Hypertens. (Greenwich). 2011; 13(2): 81-8.

White W.B. et al. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension // Hypertension. 2011; 57: 413-420.

Yuhei Shiga et al. Comparison of Effcacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension A Randomized and Prospective Study (CANZONE Study) // Int. Heart J. 2017; 58: 416-421.

Greathouse M., A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations? // CHF. 2002; 8: 313-320.

Volpe M. et al. Is early and fast blood pressure control important in hypertension management? // Int. J. Cardiol. 2017. https: //doi.org/10.1016/j.ijcard.2017.12.026

Julius S.E. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. 2004; 363: 2022-2031.

Mark A. Munger. Use of Angiotensin Receptor Blockers In Cardiovascular Protection Current Evidence and Future Directions // P&T. 2011; Vol. 36, № 1.

Инструкция для медицинского применения Аттенто № 77 от 09.02.2016.

Mancia G. et al. 2013 ESH/ESC Guidelines for the ma-nagement of arterial hypertension // Eur. Heart J. 2013; 28(34): 2159-2219.

Volpe M. et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study // Clin. Drug. Investig. 2009; 29: 11-25.

Mourad J.J. et al. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study // Clin. Drug. Investig. 2009; 29(6): 419-25.

Fogari R. et al. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients // Adv. Ther. 2010; 27(1): 48-55.

Ram C.V. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies // Curr. Med. Res. Opin. 2009; 25(1): 177-85.

Cabrera Sole R. Olmesartan plus amlodipine compared to valsartan plus amlodipine reduce more left ventricular hypertrophy and arterial stiffness in mild to moderate hypertensive patients // Journal of Hypertension. 2015; Vol. 33: e-Supplement 1.

Wang, Kang-Ling et al. Central blood pressure and cardiovascular risk // Journal of Hypertension. 2009; Vol. 27,

Is. 8:1713-1714.

Williams B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. 2006; 113(9): 1213-25.

Luis Ruilope et al. The Fixed-Dose Combination of Olme-sartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomi-zed, Double-Blind Trial in Patients with Hypertension Adv. Ther. 2013; 30: 1086-1099.

Redòn J. et al. Comparative study of the efficacy of olme­sartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes // Journal of Hypertension. 2016; 34: 359-367.

Ogihara T., Saruta T., Rakugi H. et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial // J. Hypertens. 2014; 32(10): 2054-63.

https: //www.medscape.com/viewarticle/844317




DOI: https://doi.org/10.22141/2224-1485.1.57.2018.125494

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru